Sigma Pharmaceutical

Fortescue: Best Performing Stock for the Week 46 of 2007

Sat, 17/11/2007 - 01:56

Fortescue was the overall best performing stock taking in a 15.72 percent increase. It was a mixture of metal & mineral, securities services, pharmaceuticals and mining that were among the best performing stocks for the Australian sharemarket for week 46 of 2007: Fortescue Metals (FMG), Computershare (CPU), Sigma Pharmaceutical (SIP), Iluka Resources (ILU). These best performing stocks managed gains over 9.93 percent by the end of the trading week.

AGL Energy (AGK): Loser

Sat, 13/10/2007 - 04:56

AGL Energy (AGK) was the overall worst performing stock taking in a 4.4 percent decrease. Among the worst performing stocks for the week 41 of 2007 of the Australian sharemarket were a mixture of energy, pharmaceuticals and newspaper: AGL Energy (AGK), Sigma Pharmaceutical (SIP), WA Newspapers (WAN). These worst performing stocks recorded losses higher than 4.22 percent by the end of the trading week. Both the ASX 100 index and the ASX 200 index had the same companies in the top three positions for the worst performing stocks.

SP Ausnet (SPN): Loser

Sat, 22/09/2007 - 00:56

SP Ausnet (SPN) was the overall worst performing stock taking in a 10.71 percent decrease. It was a mixture of financial services, healthcare, energy and forest products companies who were among the worst performing stocks for the week 38 of 2007 on the Australian sharemarket: Bendigo Bank (BEN), Ansell (ANN), Sigma Pharmaceutical (SIP), SP Ausnet (SPN), Adelaide Bank (ADB), Gunns (GNS). These worst performing stocks for the week 38 recorded losses above 6.08 percent by the end of the trading week.

Australian Pharmaceutical Industries (API) Stock Recommendation

Mon, 09/10/2006 - 05:40

Sigma Pharmaceutical (SIP) is bidding for Australian Pharmaceutical Industries (API), a pharmaceutical wholesaler. Sigma Pharmaceutical have announced a bid of $2.20 per share for Australian Pharmaceutical Industries but the market expects another bid as shares surge in API. Stock analyst, Macquarie Research Equities (MRE) said that "expect further bidding to continue, with the key question remaining how much one would pay." MRE expects to see further bidding to continue and likely to come from Symbion (SYB).

Syndicate content

Free Email Subscription to Share Trading

 My Share Trading Feed